Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
ConclusionsIntroducing VEN+G among first-line CLL treatments to a US health plan resulted in cost savings compared to a plan with chemoimmunotherapies and Ibr-based therapies only. Economic benefits of VEN+G, a novel agent with fixed treatment duration, coupled with proven clinical benefits should help inform formulary adoption decisions and treatment recommendations.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Health Management | Leukemia | Rituxan | Study | USA Health